Table 2 Adverse events and end-of-cycle 1 dose-limiting toxicities
From: A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer
Dosage by grade | |||||||
---|---|---|---|---|---|---|---|
2.5 mg Daily ( n =6) | 5 mg Daily ( n =11) | 10 mg Daily ( n =3) | All ( n =20) | ||||
Adverse events b | 1/2 | 3/4 | 1/2 | 3/4 | 1/2 | 3/4 | Any grade |
Haematologic toxicities | |||||||
Anaemia | 5 | 0 | 10 | 1 | 3 | 0 | 19 |
Neutropenia | 3 | 1 | 3 | 6 | 1 | 2 | 16 |
Thrombocytopenia | 2 | 0 | 3 | 1 | 2 | 2 | 12 |
Febrile neutropenia | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
Leukopenia | 4 | 1 | 4 | 4 | 2 | 0 | 15 |
Nonhaematologic toxicities | |||||||
Anorexia | 2 | 0 | 3 | 0 | 1 | 0 | 6 |
Vomiting | 0 | 0 | 2 | 0 | 0 | 0 | 1 |
Stomatitis | 2 | 0 | 5 | 0 | 1 | 0 | 8 |
Diarrhoea | 0 | 0 | 2 | 0 | 1 | 0 | 3 |
Neuropathy | 1 | 0 | 3 | 1 | 2 | 0 | 7 |
Pain | 2 | 0 | 6 | 0 | 2 | 0 | 10 |
AST increased | 1 | 0 | 4 | 0 | 1 | 0 | 6 |
ALT increased | 1 | 0 | 5 | 0 | 0 | 0 | 6 |
Hyperglycemia | 6 | 0 | 9 | 0 | 2 | 1 | 18 |
Hypertriglycemia | 3 | 0 | 2 | 0 | 2 | 0 | 7 |
Itching | 0 | 0 | 2 | 0 | 2 | 0 | 4 |
Pneumonitis | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
Dose-limiting toxicity, cycle 1 | |||||||
Thrombocytopenia | 0 | 0 | 0 | 1a | 0 | 1 | 2 |
Fever with grade 4 neutropenia | 0 | 0 | 0 | 1a | 0 | 0 | 1 |
Hyperglycemia | 0 | 0 | 0 | 0 | 0 | 1 | 1 |